Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1. - 76. (cancelled)

77. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from compounds of formulae A1 to A14, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

- Y represents O, S or NR4;
- R1, R2, R3 and R4 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or

substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

 heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A1 via a C atom or a heteroatom;

$$\begin{array}{c}
R10 \\
N = \\
R3
\end{array}$$
R3

wherein

- R1, R2 and R3 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula A2 via a C atom or a heteroatom;

- X represents O, S, NH or NR9;
- a basic five-membered ring structure may additionally contain up to three further heteroatoms as defined for X, which may be identical or different;

P29677.A01

- a basic five-membered ring structure may contain zero to two double bonds;
- R1 to R9 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A3 via a C atom or a heteroatom;

- R1, R2, R3 and R4 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A4 via a C atom or a heteroatom;

wherein

- R1, R2 and R3 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A5 via a C atom or a heteroatom;

- Y1 and Y2 represent O, S, NH, NR4 or NR5;
- Z represents S or P;
- R1 to R5 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or

substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and


 heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A6 via a C atom or a heteroatom;

wherein

- R1 and R2 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A7 via a C atom or a heteroatom;

- X and Z are identical or different and are independently selected from hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, and amino (NH₂, NHR1, NR1R2);
- Y represents O, S or NR3;

- R1, R2 and R3 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂- alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A8 via a C atom or a heteroatom;



- radicals R1 symbolize a substitution of a basic six-membered ring structure;
- X represents O, S, NH or NR2;
- a basic heterocyclic structure may contain zero to three double bonds and up to three further heteroatoms as defined for X;
- heteroatoms of the group X are identical or different and represent O, S,
 NH and NR2;
- R1 and R2 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or

substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

 heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A9 via a C atom or a heteroatom;

wherein

- radicals R1 symbolize a substitution of a basic ring structure;
- radicals R1 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A10 via a C atom or a heteroatom;

wherein

R1 is selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally

containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

 heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A11 via a C atom or a heteroatom;

- R1 and R2 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- X1 and X2 are identical or different and are independently selected from hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, hydroxy, thiol and amino (NH₂, HNR1, NR1R2);
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A12 via a C atom or a heteroatom;
- n is the number of C atoms between X1 and X2 and ranges from zero to four;
- radicals R1 and R2 are identical or different, as far as a number of C atoms of a bridge and different C atoms of a bridge are concerned;

R1-C≡N A13

wherein

- R1 is selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A13 via a C atom or a heteroatom;

- X represents N, CH, CR8, P, P=O, P(OH)₂, P(OH)(OR8) or P(OR8)(OR9),
 and Z represents NH, NR10, O or S;
- Y1, Y2 and Y3 independently represent O, S, NH, NR11, NR12 or NR13;
- R1 to R13 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or

- substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula A14 via a C atom or a heteroatom.

78. (new) The composition of claim 77, wherein the composition comprises at least one active ingredient selected from compounds of the following formulae, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

A1.001	CI
A1.002	HO HO CI
A1.003	HO HO Br
A1.004	HO Br
A1.005	HO-H-O-CI

A1.006	HO_N
A1.007	
A1.008	HO N O S O CI
A1.009	HO
A1.010	HO-H-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-
A1.011	O OH HO N
A1.012	HO F

A1.013	HO N
A1.014	HO-N-O
A1.015	0 0−N

A2.001	HO-NON
A2.002	N N
A2.003	

A2 004	N-O
A2.004	H ₂ N N
	N-N OMe
A2.005	
A2.006	H_2N N S S S
A2.007	NH ₂ NH ₂ O
A2.008	
A2.010	

A3.001	0 0
7.0.007	人人人
	Y I I o
	s N N
	\ 0
A3.002	Q
	0
) <u> </u>
	H ₂ N O
	0
A3.003	Ŷ
	CI ON NO
	CI
A3.006	
710.000	
	HO-N O
	N
A3.007	N
	0 N-H
	O H ₂ N
40.000	
A3.008	N N

A3.009	
A3.010	
A3.011	
A3.012	O H ₂ N H
A3.014	

10045	
A3.015	Br
	SYO
	o
A3.016	Br
	N-N
	S. J. N.
A3.017	<u></u>
	N.
	°
	CI
A3.018	
	o No
	0-5
A3.019	Br O

A3.020 O NH ₂	
, o ,	
_ / NH_	
O NIT ₂	
A3.022	
N—	
0=	
CI CI	
A2 022	
A3.023	
O NO	
A 2 00 4	
A3.024	
s	
Ŋ-N	
_h, }	
` ` · · · · · · · · · · · · · · · · · ·	
A3.025	
$N \longrightarrow N$	
N N	
N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.	
N-0	
A3.026	
O N S N	
ö	
,	
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	

A3.027	
A3.029	
A3.030	ON O O CI
A3.031	N O Br
A3.032	
A3.033	

A3.035	/_N
	s
	~ 0 1
A3.037	0, N-0-
	O NO
A3.038	
	N-N-N-F
A3.039	/=\
	N-N O
	ci'
A3.040	
	0 N-("\
	
A3.041	N N O
	N N
	NN-N N
	N-O'
A3.042	
	O N
	N O O
	N

A3.043	
	Br O
A3.045	
A3.046	O CI
A3.047	S 9 NH ₂
A3.048	
A3.050	
A3.051	CI N N N N N N N N N N N N N N N N N N N

A3.052	O N-N O
A3.053	
A3.054	
A3.055	
A3.056	
A3.057	

A3.058	
A3.059	
A3.060	F O N N O O
A3.061	
A3.062	
A3.063	O NH ₂

A3.064	4
	N.N.N.N.
	"
A3.065	S N N
	CI NO
A3.066	F
	N N
	O' N=
A3.067	HN
A3.068	N N N O
A3.069	CI
	0

A3.070	CI, N
	O CI CI
A3.071	
A3.072	
A3.073	
A3.074	
A3.075	N-N
A3.076	CI—O_N-N-O

A3.077	
A3.078	S N S Br O
A3.080	/
	N N N O
A3.081	
A3.082	ON NO
A3.083	N.N.N.N.

A3.084	~
710.004	[
	N-N O
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
A3.086	/
	,cı 🔨
	N N
	" 🕌
	0-
A3.087	9
	\ \ \ \ \ \ \ \ \ \ \ \
	N CI
A3.088	
A3.000	0 N-N
	\ _\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	NO
	/
A3.089	9
	N O
	ļi l
	N
A3.090	
	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
A3.091	
	N N
	N_N_
	0

,	
A3.092	N-N-O
	CI
A3.093	I N-N N N
A3.094	
A3.095	
	N-N-N-N-O
A3.097	0=\$=0 N N
A3.098	

A3.099	S N N N N N N N N N N N N N N N N N N N
A3.100	
A3.101	N N N N O O O Br
A3.102	
A3.103	N - N - N - N - N - N - N - N - N - N -
A3.104	CI NO

A 2 40E	N N
A3.105	N N
	O N N
	/
A3.106	
	0
	N N N N N N N N N N N N N N N N N N N
	~
	0
A3.107	
	N N
	N
	N N
	N-
	N
A3.109	Br O
	N N N
	Br Br
A3.110	
	O N-N
	O CI
A3.111	-0.
7.0.77	
	s
	ОТОН
A3.112	2
	CI TI

A3.113	
A3.114	Z H Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
A3.115	
A3.116	HO
A3.117	

A3.118	
A3.120	
A3.121	NH O NH CI
A3.122	N=N N O S. O
A3.124	N N P N S N

A0.405	
A3.125	N N N
	O O Br
A3.128	
A3.129	
A3.130	
A3.131	O N-N-N-Br
A3.132	

A3.133	
A3.134	
A3.135	
A3.136	
A3.137	HONN FF
A3.138	

A3.139	
A3.140	To In Mo
A3.141	
A3.142	
A3.143	N N O O Br
A3.144	
A3.145	N S N N

A2 440	
A3.146	CI
A3.147	
A3.148	Br N O
A3.149	N-(-)
A3.150	O N N Br
A3.151	S H
A3.152	

A3.153	
A3.154	
A3.155	Br O N-N-O
A3.156	N-N-N-N-F
A3.157	
A3.158	CI CI N N N
A3.159	

A2 400	0.
A3.160	N-N-O
A3.161	0. N+0- N N O
A3.162	
A3.163	
A3.164	
A3.165	
A3.166	

A3.167	, N
	N-N-N-N
A3.168	
A3.100	
	0, 1, 1
A3.169	
	O N N O
A3.170	/
	0 N 0
	N=N
	`s—он
	\ 0
A3.171	S. J
	N _N
	€ 0
A3.172	
	0 N Y O
	o'
A3.173	9 9

A3.174	o o s n n n
A3.175	CI O
A3.176	N O O
A3.177	
A3.178	
A3.179	O N N CI
A3.180	

A3.181	,0-
	O N=
A3.182	2 0
A3.102	N-N N
A3.183	0>/
	N-N
A3.184	
A3.185	=N 0
	N-N
	<u></u> _,∼
A3.186	
	N N
	N N
A3.187	0 N O CI
	N CI
	CI
L	

A3.188	
A3.189	O N N O
A3.190	NH O NH O NH O NH O NF
A3.191	N-N O
A3.192	Br O N N O
A3.193	CI—CI—N

10.404	
A3.194	N
A3.195	F F——F
	N-N
	N N N
	ó/
A3.196	
	N-O N
A3.197	ÇI
A3.197	N CI
	\mathbb{N}
	Ö
A3.198	
	. /

A3.199	
A3.200	0=N
A3.201	
A3.202	NH ₂ O
A3.203	
A3.204	S Br N S N

A3.205	HN-NOONOONOONOONOONOONOONOONOONOONOONOONO
A3.206	CI N N N N
A3.207	N-N-N-F
A3.208	
A3.209	
A3.210	N-N-N-O CI

	<u> </u>
A3.211	N-N-O
A3.212	N-N-0
A3.213	N-N-S N-N-N-N
A3.214	
A3.215	S Br
A3.216a	
A3.216b	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-

A3.217	Br—ON-NO
A3.218	JOIN NO
A3.219	
A3.220	CI
A3.221	CI
A3.222	
A3.223	HN S
A3.224	O CI CI O S

40.005	0.
A3.225	О—ОН
	N HOOO
A3.226	F——N—O N-O
A3.227	
A3.228	
A3.229	0—————————————————————————————————————
A3.230	
A3.231	0 0 0

A3.232	N N N N N N N N N N N N N N N N N N N
	N 1
A3.233	<u> </u>
	CICIONO
A3.234	
A3.235	Br
	O // \
	O, N-N
A3.236	
A2 227	0
A3.237	
	N N N N O
	0

A3.238	,0
A3.239	
A3.240	
A3.241	
A3.242	F N N N N N N
A3.243	

A3.244	
A3.245	
A3.246	
A3.247	ON NOTO
A3.248	Br N-N
A3.249	

A3.250	N O
A3.251	N N N N
A3.252	Br—OOOOO
A3.253	Br O O
A3.254	
A3.255	N-N O
A3.256	O HN S-

10.055	Ţ
A3.257	O F F F N N O O O
A3.258	H O O
A3.259	ON INNIO
A3.260	N O O O O O Br
A3.261	S N
A3.262	H_2N N N N N
A3.263	N N N N N N N N N N N N N N N N N N N

A3.264	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
A3.265	
A3.266	N F F F F F F F F F F F F F F F F F F F
A3.267	O N N O O O O O O O O O O O O O O O O O
A3.268	
A3.269	N N N

A3.270	CI
A3.271	ON NO ON O
A3.272	N-()
A3.273	
A3.274	
A3.275	
A3.276	0 0 0

A2 277	0
A3.277	N-S
A3.278	N-N O
A3.279	
A3.280	N N N N N N N N N N N N N N N N N N N
A3.281	O N O N
A3.282	S N-N
A3.283	N-N O

A3.284	CI N.N.
A3.285	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
A3.286	
A3.287	ON O
A3.288	
A3.289	
A3.290	
A3.291	S N N O

A3.292	
A3.293	
A3.294	
A3.295	
A3.296	N-N-N-F
A3.297	S N O N O
A3.298	

A3.299	N O F F F F F F F F F F F F F F F F F F
A3.300	
A3.302	CI_N, I
A3.303	CI N. N. N. N. N. O.
A3.305	CI NO F
A3.307	
A3.309	N TO
A3.310	

A2 211	
A3.311	N Br
	H N O
	~
A3.312	
	N N
A3.313	
	OH N
	0,5
	Br
A3.314	Br Q
A3.315	N N
	N-N O
	N. 0-
A3.316	⟨N
	s o
	P
A3.317	
	, ·
	ρ >
	N N
	N N N

A3.318	O O O
10.040	
A3.319	
·	HN O
	N N
A3.320	N-W
A3.321	(°)
	0-\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	но он
A3.322	CI
A3.323	N N

A3.324	
A3.325	
A3.326	H ₂ N N N N N N N N N N N N N
A3.327	
A3.328	
A3.329	

A3.330	HN-N-S
A3.331	N-N O
A3.332	O N N N S
A3.333	F N N N
A3.334	N.N.N.N.O.
A3.335	
A3.336	NH ₂
A3.337	N N O N O N O N O N O N O N O N O N O N

A3.338	N S N
A3.339	
A3.340	
A3.341	
A3.342	HN O
A3.345	

A3.346	
A3.347	O N N O
A3.348	
A3.349	
A3.350	CI

A3.351	
A3.352	

A4.001	
A4.002	Br N-N
A4.003	Br O Br

A4.004	
A4.005	
A4.006	
A4.007	
A4.008	
A4.009	Br O O

A4.010	Br ,
	Br—Q O
	O N-N, /=
	Br Br
A4.011	
	N
	N-N" To
	0 0 0 0 0 0
A4.012	Q
	O Br O
	N N Br
A4.013	
	N S O
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	0
A4.014	
	O N-N N
	0
A4.015	
	CI N-N O
A4.016	N N O
) N N
	, , , , , , , , , , , , , , , , , , ,
	N~O

A4.017	9
	Br O N N N O
A4.018	
	0 0- 1 ,0
A4.019	N N N N
A4.020	٥٥٥
	CI N N N
A4.021	N-N
	s o
	N N
A4.022	N—(0
	N N N
	N-O N-O
A4.023	
	N N

A4.024	₿r
	Br Q
	0 N N N N N N N N N N N N N N N N N N N
	Br Br
A4.025	
A4.025	
	, o , i
44.000	F . ~
A4.026	
	O TIME
A4.027	
	N.N.N.N.N.
	O N N
A4.028	
	N-N=
A4.029	
	N N
	N
A4.030	4
	N.N.N.N.N.
L	

A4.031	F
A4.031	
	7
	N N
	N N
) N
	N=_O
A4.032	N N O-
	N N N
	0-N
A4.033	
	`o(_>-oo
	Br N-N,
	Br O
A4.034	0 07
1	0 N N N
A4.035	9 . / \
	,N - -()(
	O — N-N
	<u> </u>
	,
A4.036	
	`O N N
	• 🗡
	◎
A4.037	
	\ N-N
	, and the second

A4.038	CI————————————————————————————————————
A4.040	
A4.041	
A4.042	O N N O
A4.043	
A4.044	CI N-N O
A4.045	N-N-N-O

A4.046	â N D
	N N N O
	CI CI
A4.047	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
A4.048	
	, , N
	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
A4.049	
	0=\$=0
	N N
A4.050	s >
	O N N
	<u> </u>
A4.051	
	N N N N N N N N N N N N N N N N N N N
	O O

A4.052	N N N N O O Br
A4.053	
A4.054	
A4.055	
A4.056	Br O Br O Br
A4.057	N-N-N-CI
A4.058	

A4.059	o Br Br
	O N N Br
A4.060	ON NOBr
A4.061	
A4.063	
A4.064	O N-N Br
A4.065	
A4.066	

A4.067	
	H ₂ C O N-N NH CH ₃
	H₃C N-N
A4.068	•
7,	
	N N
	N-N
A4.069	
	N I
	N N N N O
	_\ ⁰
A4.070	SOLN D
	N W W
A4.071	N N N
A4.072	0
	N-N
A4.073	
	"O O N= O
	Br O

A4.074	O
	N N N N N N N N N N N N N N N N N N N
	Br N O
A4.075	Br
	N N N Br
A4.076	s o o o
	N N-N /=
	N=0
	o ⁻
A4.077	
	O N N
	o-N-O Ö
A4.078	CI—O O N-O-
	N-N
A4.079	Br
	N-N-O
A 4 000	\
A4.080	N-N N N
	F
1	

A4.081	CI
A4.082	
A4.083	N-N O
A4.084	
A4.085	
A4.086	

A4.087	N-N N-N O
A4.088	
A4.089	S-NNNNNO
A4.090	S N N N N N N N N N N N N N N N N N N N
A4.091	
A4.092	o s N N O
A4.093	

A4.094	
A4.095	
A4.096	N-W O
A4.097	
A4.098	
A4.099	O N N O
A4.100	N-N O
A4.101	Br O N N O

A4.102	N N N
A4.103	ON CI
A4.104	0
A4.104	
	N N N N N N N N N N N N N N N N N N N
A4.105	
A4.106	CI N N N N
A4.107	H ₃ C N N HO
A4.108	N-N-N-F

A4.109	N-N-N-CI
A4.110	N-N-N-O
A4.111	N-N
A4.112	
A4.113	
A4.114	
A4.115	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-

A4.116	
/	Br—ON-N
A4.117	9
	N N N O
A4.118	
	O N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
A4.119	
	O N
	CI N O
A4.120	
	N _N
A4.121	
A4.121	
	N-N O-
	N N N N N N N N N N N N N N N N N N N
A4.122	o-√^_
	o N-N
A4.123	0>
	N N
	0 N-N
	0

A4.124	O Br O Br
A4.125	
A4.126	Br O Br O Br O Br
A4.127	
A4.128	
A4.129	
A4.130	N N N N N O
A4.131	N-N-O

A4.132	0 N-N N-0-
A4.133	
A4.134	Br O N-N
A4.135	
A4.136	
A4.137	Br O O

A4.138	5
	N N N N N N N N N N N N N N N N N N N
	s— o=
	Ō
A4.139	N-N $N-N$ O
A4.140	CIN IN NO
A4.141	S N-N
A4.142	N N TO
A4.143	[]_N_N
A4.144	S N-N
A4.145	X O I N N Y O

A4.146	
A4.147	O N N Br O Br
A4.148	
A4.149	N-N N-N
A4.150	
A4.151	S N-N
A4.152	N-N O
A4.153	

A4.154	TO N-N N
A4.155	
A4.156	
A4.157	S N N N
A4.158	N-N-N
A4.159	N-N F
A4.160	
A4.161	

A4.162	C2=N.N.I
A4.163	CI N, N N N N N N N N N N N N N N N N N N
A4.164	O N N Br O Br
A4.166	
A4.167	P O N N O
A4.168	
A4.169	

A4.170	
	N N
	, o
A4.171	Br O N N N
A4.172	N-N O
	N.O.
A4.173	O O O O O O O O O O O O O O O O O O O
	N N
A4.174	
	N N-N
24.475	
A4.175	s
	N N N
	0 N N=
A4.176	N N
	O N-N N
	0

A4.177	N-N O
A4.178	S N-N
A4.179	N-N O
A4.180	F N N N
A4.181	N.N.N.N.N.O.
A4.182	
A4.183	

A4.184	N N N O
A4.185	
A4.186	N-N N
A4.187	

A5.001	
	O N
	į, h
) °
	Ci'

45.000	
A5.003	
	o (
	Ø Br
	Ϋ́
	Br
A5.004	
	N, ,N
	\\\\\
-	P N N
A5.005	
	0
	I I P
	CI
A5.006	
1,0,000	/ \
	()
	\sim
	<u> </u>
	N=_\
	N=
	<u>_</u> "

A5.007	
	>_/
	(X
	N=\
	`

A6.001	
A6.002	
A6.003	но

A6.004	
710.004	
	s
	o=\$=0
	HN
	()
	HN
	· · · · · · · · · · · · · · · · · · ·
	NH ₂
A6.005	
	S. H.
	0
	Š
A6.006	
Λυ.υυυ	_
	O
	H _z N N O S
	§ J F
A6.007	
	O=P-()
	0-1/20
	07170

A6.008	
A6.009	
A6.010	
A6.011	O H CI

A6.012	N=N O
A6.013	
A6.015	CI CI
A6.016	
A6.017	

A7.001	
	7
	S
47.000	<u> </u>
A7.002	
	»—s
	_n
	\
A7.004	
	S H
	S S
A7.005	
	,o
	$\circ = \langle$
	o /-s
	NN
	l s
	·

A7.006	
A7.007	
A7.008	S
A7.010	O H CI
A7.011	HO
A7.012	HN S

A8.001	H_2N
A8.002	
A8.003	Br O S O O S O O O S O O O O S O O O O O
A8.004	
A8.005	S N S N F

A8.006	
	S N=
A8.007	H ₃ C
A8.008	You No
A8.009	O N S
A8.010	
A8.011	
A8.012	S N S
A8.013	

A8.014	S-N CI
A8.015	HZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
A8.016	
A8.017	
A8.018	O N-N N N O

A8.019	HO
710.010	
	, N s
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
	0 N
A8.020	\Diamond 0
	N N
	s ^{-N} ()
40.004	
A8.021	9 🖺
	H ₃ C N S
	ONNNN CH ₃
	CH ₃
A8.022	.0
7.0.022	
	S N
	N_N
	~°~
A8.023	0
	H_3C_N N S
	N S
	O' N' N' H
A8.024	
	N → O
	, ni
	T _N

40.005	
A8.025	
A8.026	
	O S N N O
A8.027	NH O N N N N N N N N N N N N N N N N N N
A8.028	
A8.029	S N N N N N N N N N N N N N N N N N N N
A8.030	CH ₃ CH ₃ CH ₃ CH ₃

A8.031	
A8.032	S N-N
A8.033	O H O O O O O
A8.034	NH ₂ N CI CI CI
A8.035	
A8.036	

A8.037	
A8.038	O N O N
A8.040	
A8.041	HN O HN O F

A9.001	
A9.002	CI ON N

A9.003	
A9.005	
A9.006	Br O S O
A9.007	Br N-N-O
A9.008	
A9.009	

Λ0.010	
A9.010	
A9.011	
A9.012	
A9.013	S N S F
A9.014	H ₃ C O

A9.015	
A9.015	ON CI
A9.016	
A9.017	O=N N
A9.018	CH ₃ CH ₃ CH ₃ N N N CH ₃
A9.019	
A9.020	

A9.021	
A9.022	
A9.023	
A9.024	H ₃ C N CH ₃
A9.025	
	N O CI

A9.026	
A9.027	Y ∘ - () • N · O · O · O · O · O · O · O · O · O ·
A9.028	CI F O O
A9.029	
A9.030	O_N+_O_
A9.031	H ₂ N N O S O

A9.032	OH ONH
A9.033	S N N N
A9.034	S N N N O
A9.035	
A9.036	CI

A9.037	
	Br O N O
	0
A9.038	HO_N F
	O N N
A9.039	N S N N N N N N N N N N N N N N N N N N
A9.040	CI N
A9.041	O N-N N N-O
A9.042	

A9.043	
A9.044	
A9.045	
A9.046	
A9.047	N-(-)
A9.048	CH ₃ N N N N N NH ₂

A9.049	CI
A9.050	
A9.051	
A9.052	O HO O

A9.053	
A9.054	CI N-O
A9.055	H ₃ C CH ₃ NH O CH ₃ NH CH ₃ CH ₃ CH ₃ CH ₃ NH CH ₃
A9.056	
A9.057	

A9.058	
	0
A9.059	
A9.060	H ₃ C CH ₃ H ₃ C N CH ₃
A9.061	
A9.062	Br — O — N — O — O — N — O — O — O — O — O
A9.063	

A9.064	>
	CI
	0
A9.065	
A9.066	
A9.067	0
	N N N N N N N N N N N N N N N N N N N
A9.068	
	N S
A9.069	CH ₃ O CH ₃
	H ₃ C CH ₃

A9.070	
A3.070	CH ₃ CH ₃ OH OH
A9.071	
A9.072	CI O
A9.073	
A9.074	

A9.075	O Z O O
A9.076	
A9.077	HN N O
A9.078	
A9.079	
A9.080	N CI CI

A9.081	N _E O
	(_N)
	N PO
A9.082	Q II
	ОН
	H,C, J, s
	"
	ĊН ₃ ĊН ₃
A9.083	Zii
	CI
A9.084	F
	F + F
	N—(N)
	N N
40.005	97
A9.085	CI N
	N CI
	N V
	Ö
A9.086	0 7
	s i v
	N-N"
1	

A9.087	O S Br
A9.088	ó N S)/N
	N O O N
A9.089	
A9.090	
A9.091	CI
A9.092	O CI CI O

A9.093	OH OH NH HO
A9.094	CI
A9.095	CH ₃ CH ₃ CH ₃ CH ₃
A9.096	
A9.097	O OH S-CH ₃

A9.098	
A9.099	
A9.100	CH ₃ CH ₃ OH O
A9.101	CI
A9.102	

A9.103	
A9.104	
A9.105	NH ₂ N CH ₃ CI CI
A9.106	

126


A9.107	
A9.108	0>0
	Ŋ
	N N N
	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
A9.109	_S_
A9.110	
A9.111	
	N N
	-0
L	

A9.112	
	SOH
	N N
	ĊH ₃ ĊH ₃
A9.113	
A9.114	
	CI
A9.115	
	H F F
A9.116	
	N=\
A9.117	

A9.118	
	H₃C H₃C
A9.119	H ₃ C H ₃ C H ₃ C H ₃ C
	Nсн
A9.120	H ₃ C N CH ₃
	O—H ₃ C CH ₃
A9.121	CI

A9.122	F F O CH ₃ O O O O
A9.123	HN N O=N O
A9.124	Z=Z
A9.125	

A9.126	
A9.127	
A9.128	O, → O - N - N - N - N - N - N - N - N - N -



A10.003	
	N CI
A10.004	HO_N CH ₃
	CH ₃
A10.005	
A10.006	$N \longrightarrow N \longrightarrow$
A10.007	N

A10.008	O N O N O Br
---------	--------------

A11.001	N N N N
A11.002	N-N-O-
A11.003	Br O O O O O O O O O O O O O O O O O O O
A11.004	O=N = N
A11.005	
A11.006	

A11.007	
A11.008	H ₃ C CH ₃
A11.009	0, 2
A11.010	
A11.011	O=P
A11.012	O.N.O.

A44.042	
A11.013	
A11.014	
A11.015	0 N-0 O F
A11.016	Br — N — O — N — O — O — N — O — O — O — O
A11.017	
A11.018	0. N-O- N-O- N-O-

A44 040	
A11.019	
A11.020	
A11.021	HN O F F F
A11.022	O=N-OCH3
A11.023	
A11.024	0=N

A11.025	O NH ₂
A11.026	
A11.027	F——N 0 N 0
A11.028	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
A11.029	
A11.030	NH O N+O
A11.031	

A11.032	O N O O
	F N N N N N N N N N N N N N N N N N N N
A11.033	O N O N
	O O
A11.034	0, N O N O N O N O N O N O N O N O N O N
A11.035	
A11.036	
A11.037	

A11.038	
A11.039	O-N, O O O

A12.002	O Br Br O O O
A12.003	CI
A12.004	
A12.005	

A12.006	CI
	но
	0
A12.007	
	0 10 0
A12.008	H O Br
	HO_IN_
A12.009	Br
	HO HO
	0
A12.010	
	N N
	Ñ-N >= 8
A12.011	Chiral
7.12.017	
	N H O N H O
	N O
	, N , N , N , N , N , N , N , N , N , N
	•
A12.013	HO_N

A12.015	
A12.016	
A12.017	HO N CH ₃
A12.018	N-O-NONO
A12.019	

A12.021	H 0.00
	HO N O S
	CI
A12.022	>
	\ \ \ \
	CI
	oly o
A12.023	O H ₃ C CH ₃
	HO
	H ₃ C-N N N
	N 0-
	N, N
A12.024	,o
	0=
	S
A12.025	Y0-(-)-(-)-(-)-(-)-(-)-(-)-(-)-(-)-(-)-(-
	N N
	<u></u>
A12.026	
	CI

A12.027	Ŷ
	N S
A 40 000	s N
A12.028	HO HO
A12.029	HO_H_O
A12.030	
	Br
	0 0 0
A12.031	O OH
	HO N N
	N F
A12.032	s—N=
	N—CI
A42.022	° cı Cı
A12.033	
	N-(III)
A12.034	`o
7112.004	
	N N
	III N

A12.035	
	N O
	N PO
A12.036	
	N H H
A12.037	N/
	N N
	•
	N H
A12.038	N O
A12.030	
	N CO
	N _y o
A12.039	H ₂ N
	но
	HN

A12.040	
	F F F
A12.041	tı F
	HO HO F
A12.042	F H₃C CH₃
	но
	H ₃ C N N N
	N F
	F
A12.044	H. A.
	HO TO
A12.045	
	, s
	N N
A12.047	
	N
	Ċ°

A12.048	N III
	CI
A12.049	/
140.050	F F F
A12.052	
	0 N-
	N /
A12.053	
	HO HOO
	ö
A12.054	S Br
A12.055	ő
	H ₃ C CH ₃

A12.056	N N N N S F O
A12.058	Br—OOOO
A12.060	O OH N S-CH ₃
A12.061	F F O O NH OH OH
A12.063	

A12.065	
440,000	F
A12.069	0 0 0-N
A12.070	
A12.072	H ₃ C CH ₃ HO OH

A13.001	CI
	CI'

A13.002	
A13.003	
A13.004	
A13.005	CI N-N O
A13.006	CI
A13.007	Br O N O

A13.008	CI N
A13.009	
A13.010	
A13.011	CI ON
A13.012	

A13.013	
7113.313	
	N
A13.014	Z =
	ci
A13.015	°, N ⁺ -O ⁻
) o n
A13.016	ONNO
	CI
	Vol.
A13.017	N III
	CI-CI-CI-CI-CI-CI-CI-CI-CI-CI-CI-CI-CI-C
110 010	/ 0
A13.018	N CI
	CI—
	Ö

A13.019	S Br N S N
A13.020	CI
A13.021	Br—OOOOO
A13.022	N O F F F F F F F F F F F F F F F F F F
A13.023	CI
A13.024	CI

A14.001	
A14.002	
A14.003	

79. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 77 and an active ingredient thereof, alone or in combination with one or more inhibitors of dipeptidyl peptidase IV or analogous enzymes.

80. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof, alone or in combination with one or more inhibitors of dipeptidyl peptidase IV or analogous enzymes.

81. (new) A method of topically influencing an activity of at least one enzyme selected from alanyl aminopeptidases and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of a composition of claim 77 and an active ingredient thereof, alone or in combination with one or more inhibitors of dipeptidyl peptidase IV or analogous enzymes.

82. (new) A method of topically influencing an activity of at least one enzyme selected from alanyl aminopeptidases and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of a composition of claim 78 and an active ingredient thereof, alone or in combination with one or more inhibitors of dipeptidyl peptidase IV or analogous enzymes.

83. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale and other allergic diseases; rejection of transplanted tissues and cells; skin and mucosa diseases such as psoriasis and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states; acute neuronal diseases, in particular ischemia-caused cerebral damage after an ischemic or hemorrhagic stroke, cranio-cerebral

trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer. Pick's disease. Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Morbus Parkinson, in particular Morbus Parkinson coupled to chromosome 17, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal disease (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 77 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

84. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale and other allergic diseases; rejection of transplanted tissues and cells; skin and mucosa diseases such as psoriasis and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states; acute neuronal diseases, in particular ischemia-caused cerebral damage after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's

disease, Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Morbus Parkinson, in particular Morbus Parkinson coupled to chromosome 17, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal disease (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

85. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 77 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

86. (new) The method of claim 85, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

87. (new) A stent which is coated with at least one of a composition of claim 77 and an active ingredient thereof.

88. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

89. (new) The method of claim 88, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

90. (new) A stent which is coated with at least one of a composition of claim 78 and an active ingredient thereof.

91. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism at least one of a composition of claim 77 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

92. (new) The method of claim 91, wherein the method comprises administering the at least one of a composition and an active ingredient thereof at least one of as a coating or layer on the medical device and incorporated in the medical device.

93. (new) The method of claim 91, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by at least one of a local and a systemic administration successively or concurrently.

94. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

95. (new) The method of claim 94, wherein the method comprises administering the at least one of a composition and an active ingredient thereof at least one of as a coating or layer on the medical device and incorporated in the medical device.

96. (new) The method of claim 94, wherein the method comprises administering the at least one of a composition and an active ingredient thereof

P29677.A01

by at least one of a local and a systemic administration successively or concurrently.